IL2 and neoplasm: Adaptive resistance in “cold” or exhausted tumors; systemic IL-2 toxicity; low local immunostimulatory concentration;Immune toxicity and organ safety by lowering activity in healthy tissues; partial PK/penetration leverage via higher tolerated tumor-directed exposure